Eulav Asset Management Insulet Corp Transaction History

Eulav Asset Management

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$127.77 - $221.42 $190,505 - $330,137	-1,491 Reduced 17.96%	6,809 $1.48 Million
Q3 2023 Nov 13, 2023	SELL	$154.67 - $290.89 $1,392 - $2,618	-9 Reduced 0.11%	8,300 $1.32 Million
Q2 2023 Aug 09, 2023	SELL	$272.48 - $330.23 $58,038 - $70,338	-213 Reduced 2.5%	8,309 $2.4 Million
Q1 2023 Apr 27, 2023	SELL	$276.36 - $326.03 $408,460 - $481,872	-1,478 Reduced 14.78%	8,522 $2.72 Million
Q4 2022 Feb 14, 2023	SELL	$212.22 - $313.46 $212,220 - $313,460	-1,000 Reduced 9.09%	10,000 $2.94 Million
Q3 2022 Nov 03, 2022	SELL	$224.6 - $281.45 $224,600 - $281,450	-1,000 Reduced 8.33%	11,000 $2.52 Million
Q2 2022 Jul 22, 2022	BUY	$186.4 - $279.02 $2.24 Million - $3.35 Million	12,000 New	12,000 $2.62 Million
Q1 2020 Apr 27, 2020	SELL	$130.01 - $216.44 $1.59 Million - $2.64 Million	-12,200 Closed	0 $0
Q3 2018 Oct 26, 2018	SELL	$81.43 - $108.13 $618,868 - $821,788	-7,600 Reduced 38.38%	12,200 $1.29 Million
Q2 2017 Aug 14, 2017	BUY	N/A	19,800	19,800 $1.02 Million

685

62.7M

640K

881K

Ticker PODD
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 69,403,600
Market Cap $18.1B
Description
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sel...

Get notified when there are updates to the investment portfolio of Eulav Asset Management, based on Form 13F filings with the SEC.

Stay updated on Eulav Asset Management with notifications on news.